BRPI0911297A2 - composição e métodos para preparo e uso das mesmas - Google Patents
composição e métodos para preparo e uso das mesmasInfo
- Publication number
- BRPI0911297A2 BRPI0911297A2 BRPI0911297A BRPI0911297A BRPI0911297A2 BR PI0911297 A2 BRPI0911297 A2 BR PI0911297A2 BR PI0911297 A BRPI0911297 A BR PI0911297A BR PI0911297 A BRPI0911297 A BR PI0911297A BR PI0911297 A2 BRPI0911297 A2 BR PI0911297A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- composition
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4488608P | 2008-04-14 | 2008-04-14 | |
| PCT/US2008/071392 WO2009018233A1 (en) | 2007-07-30 | 2008-07-28 | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
| US15977809P | 2009-03-12 | 2009-03-12 | |
| PCT/US2009/040538 WO2009129246A2 (en) | 2008-04-14 | 2009-04-14 | Compositions and methods for preparing and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0911297A2 true BRPI0911297A2 (pt) | 2019-09-24 |
Family
ID=41199689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0911297A BRPI0911297A2 (pt) | 2008-04-14 | 2009-04-14 | composição e métodos para preparo e uso das mesmas |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8808742B2 (pt) |
| EP (1) | EP2291350A4 (pt) |
| JP (1) | JP2011518786A (pt) |
| KR (1) | KR20110014149A (pt) |
| CN (1) | CN102131771A (pt) |
| AU (1) | AU2009236325A1 (pt) |
| BR (1) | BRPI0911297A2 (pt) |
| CA (1) | CA2720671A1 (pt) |
| CO (1) | CO6331425A2 (pt) |
| CR (1) | CR11731A (pt) |
| CU (1) | CU20100200A7 (pt) |
| DO (1) | DOP2010000304A (pt) |
| EA (1) | EA201001639A1 (pt) |
| EC (1) | ECSP10010548A (pt) |
| IL (1) | IL208284A0 (pt) |
| MA (1) | MA32226B1 (pt) |
| MX (1) | MX2010011314A (pt) |
| SG (1) | SG189784A1 (pt) |
| WO (1) | WO2009129246A2 (pt) |
| ZA (1) | ZA201006944B (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
| TWI524890B (zh) * | 2009-07-24 | 2016-03-11 | 亞德生化公司 | （ｒ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺及（ｓ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺之製備 |
| BR112012003592B8 (pt) | 2009-08-19 | 2021-05-25 | Eisai R&D Man Co Ltd | composição farmacêutica contendo derivado de quinolina |
| CN102666512B (zh) | 2009-10-13 | 2014-11-26 | 奥斯特姆医疗公司 | 对疾病治疗有用的mek抑制剂 |
| PE20130191A1 (es) * | 2010-04-16 | 2013-02-21 | Bayer Ip Gmbh | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
| WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2013184572A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| CN103570594A (zh) * | 2012-08-01 | 2014-02-12 | 苏州迈泰生物技术有限公司 | 二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途 |
| EP2916859B1 (en) | 2012-11-02 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| EP2848246A1 (en) | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| WO2015036512A1 (en) * | 2013-09-13 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| CA2957005C (en) | 2014-08-28 | 2021-10-12 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| SG11201706630UA (en) | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3341739A4 (en) * | 2015-08-28 | 2019-07-10 | BioIncept LLC | MUTATED PEPTIDES AND METHOD FOR TREATING SUBJECTS THEREWITH |
| EP3341006A4 (en) | 2015-08-28 | 2019-03-13 | BioIncept LLC | COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| DK3609464T3 (da) * | 2017-04-13 | 2021-08-30 | Jean Paul Remon | Xanthohumolbaserede sammensætninger |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CN113476476A (zh) * | 2021-08-25 | 2021-10-08 | 娜布其 | 一种治疗白癜风疾病的药物及其制作工艺 |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8005A (en) * | 1851-04-01 | He ne y bo o t | ||
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| GEP20032999B (en) * | 1999-01-13 | 2003-06-25 | Warner Lambert Co | 1-Heterocycle Substituted Diarylamines |
| WO2007014011A2 (en) * | 2005-07-21 | 2007-02-01 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
| CA2924418A1 (en) * | 2007-07-30 | 2009-02-05 | Jean-Michel Vernier | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
| KR20140098185A (ko) * | 2007-07-30 | 2014-08-07 | 아디아 바이오사이언스즈 인크. | 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법 |
| US8044240B2 (en) * | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
-
2009
- 2009-04-14 US US12/937,630 patent/US8808742B2/en not_active Expired - Fee Related
- 2009-04-14 AU AU2009236325A patent/AU2009236325A1/en not_active Abandoned
- 2009-04-14 CN CN2009801180672A patent/CN102131771A/zh active Pending
- 2009-04-14 SG SG2013028378A patent/SG189784A1/en unknown
- 2009-04-14 EP EP09732683A patent/EP2291350A4/en not_active Withdrawn
- 2009-04-14 KR KR1020107025394A patent/KR20110014149A/ko not_active Withdrawn
- 2009-04-14 JP JP2011505138A patent/JP2011518786A/ja active Pending
- 2009-04-14 EA EA201001639A patent/EA201001639A1/ru unknown
- 2009-04-14 MX MX2010011314A patent/MX2010011314A/es active IP Right Grant
- 2009-04-14 BR BRPI0911297A patent/BRPI0911297A2/pt not_active IP Right Cessation
- 2009-04-14 CA CA2720671A patent/CA2720671A1/en not_active Abandoned
- 2009-04-14 WO PCT/US2009/040538 patent/WO2009129246A2/en not_active Ceased
-
2010
- 2010-09-21 IL IL208284A patent/IL208284A0/en unknown
- 2010-09-29 ZA ZA2010/06944A patent/ZA201006944B/en unknown
- 2010-10-13 CU CU2010000200A patent/CU20100200A7/es active IP Right Grant
- 2010-10-14 CR CR11731A patent/CR11731A/es not_active Application Discontinuation
- 2010-10-14 CO CO10128068A patent/CO6331425A2/es not_active Application Discontinuation
- 2010-10-14 MA MA33245A patent/MA32226B1/fr unknown
- 2010-10-14 DO DO2010000304A patent/DOP2010000304A/es unknown
- 2010-10-14 EC EC2010010548A patent/ECSP10010548A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102131771A (zh) | 2011-07-20 |
| KR20110014149A (ko) | 2011-02-10 |
| ECSP10010548A (es) | 2010-11-30 |
| EP2291350A4 (en) | 2012-09-19 |
| EP2291350A2 (en) | 2011-03-09 |
| CR11731A (es) | 2011-06-08 |
| EA201001639A1 (ru) | 2011-06-30 |
| WO2009129246A2 (en) | 2009-10-22 |
| JP2011518786A (ja) | 2011-06-30 |
| CU20100200A7 (es) | 2011-11-15 |
| IL208284A0 (en) | 2010-12-30 |
| US8808742B2 (en) | 2014-08-19 |
| SG189784A1 (en) | 2013-05-31 |
| DOP2010000304A (es) | 2011-10-15 |
| CU23904B1 (pt) | 2013-06-28 |
| CA2720671A1 (en) | 2009-10-22 |
| US20110033539A1 (en) | 2011-02-10 |
| CO6331425A2 (es) | 2011-10-20 |
| MX2010011314A (es) | 2010-11-12 |
| AU2009236325A1 (en) | 2009-10-22 |
| ZA201006944B (en) | 2015-06-24 |
| WO2009129246A3 (en) | 2011-03-31 |
| MA32226B1 (fr) | 2011-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0822104A2 (pt) | Composições antimicrobianas e métodos para o uso das mesmas | |
| BRPI0820556A2 (pt) | Bactéria e métodos para uso das mesmas | |
| BRPI0912703A2 (pt) | composições imuno-moduladoras e métodos para uso dessas | |
| BRPI0918359A2 (pt) | composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto | |
| BRPI0920891A2 (pt) | misturas de alfa-amilase e métodos para uso das referidas misturas | |
| BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
| BRPI1014800A8 (pt) | "composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas" | |
| BRPI0910852A2 (pt) | composições contendo lipídios e métodos de uso das mesmas | |
| BRPI0916630A2 (pt) | composições para uso em construção e processo de aplicação das mesmas | |
| BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
| BRPI0919193A2 (pt) | Uso de lipídeo, e, composição nutricional | |
| BRPI0919438A2 (pt) | mistura de poliésteres, e, uso das misturas de poliésteres | |
| BR112013001423A2 (pt) | método, método in vitro, uso e kit útil para realizar o método | |
| BR112012005807A2 (pt) | materiais expansíveis e mpetodos para uso | |
| BRPI0907453A2 (pt) | Compostos, uso e preparação dos mesmos | |
| BRPI0813955A2 (pt) | composições terapêuticas e o uso das mesmas | |
| BRPI0821668A2 (pt) | Uso | |
| BR112013003304A2 (pt) | composição lubrificante e composição lubrificante para uso em condições externas | |
| BR112013010988A2 (pt) | composição fluída e uso | |
| PT2868315T (pt) | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos | |
| BRPI0907365A2 (pt) | Composição antimicrobiana e uso | |
| BR112013010272A2 (pt) | métodos analíticos e arranjos para uso nos mesmos | |
| BRPI1006996A2 (pt) | composição, método e uso | |
| BRPI0812166A2 (pt) | Composições úteis para reduzir nefrotoxicidade e métodos de uso das mesmas | |
| BRPI0919794A2 (pt) | dispositivo para uso intracorpóreo, e, composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |